ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
Clinical trials for ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Gene therapy trial aims to train Patients' own cells to fight aggressive lymphomas
Disease control Recruiting nowThis early-stage study is testing whether a patient's own immune cells can be genetically modified to fight certain T-cell lymphomas that have returned or not responded to standard treatments. Doctors will collect white blood cells from participants, alter them in a lab to target…
Matched conditions: ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New pill challenges standard care for Tough-to-Treat blood cancers
Disease control Recruiting nowThis study is testing an experimental oral drug called soquelitinib against standard chemotherapy options for adults with specific aggressive T-cell lymphomas that have returned or not responded to prior treatment. About 150 participants will be randomly assigned to receive eithe…
Matched conditions: ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Corvus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC
-
New IV drug trial offers hope for patients with aggressive lymphoma
Disease control Recruiting nowThis is an early-stage study testing a new intravenous drug called ST-001 for people with T-cell lymphoma that has come back or not responded to prior treatments. The main goals are to find the highest safe dose and understand how the drug works in the body. It is for adults whos…
Matched conditions: ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: SciTech Development, Inc. • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC